

7 February 2025

Benchmark Holdings plc
("Benchmark" or "the Company")

Notice of Q1 Results

Webcast for analysts and institutional investors
Equity Development webcast for retail investors

Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will announce its Q1 results, for the three month period ended 31 December 2024, on Friday 28 February 2025.

Presentation for analysts and institutional investors at 08:00 UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a presentation for analysts and institutional investors on the day at 08:00 UK time (09:00 CET).

The presentation will be held in person at Haakon VII's Gate 2, Oslo, Norway. To register your interest, please contact benchmark@mhpgroup.com

A live webcast of the presentation will be available for analysts and investors to join remotely at the following link:
https://channel.royalcast.com/hegnamedia/#/hegnamedia/20250228_5

Equity Development webcast for retail investors at 11:00 UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a second webcast for retail investors and wealth managers at 11:00 UK time (12:00 CET). The webcast is open to all existing and potential shareholders.

To register please visit:

<https://www.equitydevelopment.co.uk/news-and-events/benchmark-q1-investor-presentation-28february2025>

Enquiries

For further information, please contact:

Benchmark Holdings plc	benchmark@mhpgroup.com
Trond Williksen, CEO	
Septima Maguire, CFO	
Ivonne Cantu, Investor Relations	

Deutsche Numis (Nominated Adviser and Broker)	Tel: 020 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah	

MHP	Tel: +447890 952 661
Katie Hunt, Reg Hoare, Samuel Garner	benchmark@mhpgroup.com

Equity Development	Tel: 020 7065 2692
Hannah Crowe	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUPUWUPUPAGGM